참고문헌
- Guo, L. and C. Wu (2002), Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex, FASEB J. 16, 1298-1300
- Pugliese, G., F. Pricci, P. Mene, G. I. Romeo, Nofroni, S. Giannini, B. Cresci, G. Galli, C. M. Rotella, U. Di Mario, and F. Pugliese (1997), High glucose level unmasks a genetic predisposition to enhanced extracellular matrix production in mesangial cells from the Milan normotensive strain, J. Am. Soc. Nephrol. 8, 406-414
- Ziyadeh, F. N. (2004), Mediators of diabetic renal disease: the case for TGF-beta as the major mediator, J. Am. Soc. Nephrol. 1, S55-57
- Massague, J. (1990), The transforming growth factor-beta family, Annu. Rev. Cell Biol. 6, 597-641
- Klahr, S. and J. Morrissey (2003), Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor, Kidney Int. Suppl. 87, S105-112
- Border, W. A. and N. A. Noble (1994), Transforming growth factor beta in tissue fibrosis, N. Engl. J. Med. 331, 1286-1292
- Ziyadeh, F. N., K. Sharma, M. Ericksen and G. Wolf (1994), Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta, J. Clin. Invest. 93, 536-542
- Dzau, V. J. (2002), Transcription factor decoy. Circ. Res. 90, 1234-1236
- Morishita, R., T. Sugimoto, M. Aoki, I. Kida, N. Tomita, A. Moriguchi, K. Maeda, Y. Sawa, Y. Kaneda, J. Higaki, and T. Ogihara (1997), In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction, Nat. Med. 3, 894-899
- Kawauchi, M., J. Suzuki, R. Morishita, Y. Wada, A. Izawa, N. Tomita, J. Kaneda, Y. Amano, T. Ogihara, S. Takamoto, and M. Isobe (2000), Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates, Circ. Res. 87, 1063-1068
- Udvadia, A. J., D. J. Templeton, and J. M. Horowitz (1995), Functional Interactions Between the Retinoblastoma (Rb) Protein and Sp-Family Members: Superactivation by Rb Requires Amino Acids Necessary for Growth Suppression, Proc. Natl. Acad. Sci. USA. 92, 3953-3957
- Li, J. M., M. B. Datto, X. Shen, P. P. Hu, Y. Yu and X. F. Wang (1998), Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites, Nucleic Acids Res. 26, 2449-2456
- Zhang, X., Y. Li, C. Dai, J. Yang, P. Mundel, and Y. Liu (2003), Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney, Am. J. Physiol. Renal Physiol. 284, 82-94
- Slansky, J. E., Y. Li, W. G. Kaelin, and P. J. Farnham (1993), A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter, Mol. Cell. Biol. 13, 1610-1618
- Ahn, J. D., R. Morishita, Y. Kaneda, H. J. Kim, Y. D. Kim, H. J. Lee, K. U. Lee, J. Y. Park, Y. H. Kim, K. K. Park, Y. C. Chang, K. H. Yoon, H. S. Kwon, K. G. Park, and I. K. Lee (2004), Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo, Gene Ther. Epub ahead of print
- Leehey, D. J., A. K. Singh, N. Alavi, and R. Singh (2000), Role of angiotensin II in diabetic nephropathy, Kidney Int. Suppl. 77, 93-98
- Hata, Y., E. Duh, K. Zhang, G. S. Robinson, and L. P. Aiello, (1998), Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence, J. Biol. Chem. 273, 19294-19303
- Ishibashi, H., K. Nakagawa, M. Onimaru, E. J. Castellanous, Y. Kaneda, Y. Nakashima, K. Shirasuna, and K. Sueishi (2000), Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities, Cancer Res. 60, 6531-6536
- Verrecchia, F., J. Rossert, and A. Mauviel (2001), Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis, J. Invest. Dermatol. 116, 755-763
- Derylo, B., T. Babazono, E. Glogowski, J. Kapor-Drezgic, T. Hohman, and C. Whiteside (1998), High glucose-induced mesangial cell altered contractility: role of the polyol pathway, Diabetologia. 41, 507-515
- Holmgren, L., M. S. O'Reilly, and J. Folkman, (1995), Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat. Med. 1, 149-153
- Ahn, J. D., R. Morishita, Y. Kaneda, H. S. Kim, Y. C. Chang, K. U. Lee, J. Y. Park, H. W. Lee, Y. H. Kim, and I. K. Lee (2002), Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia, Gene Ther. 9, 1682-1692
- Ahn, J. D., R. Morishita, Y. Kaneda, S. J. Lee, K. Y. Kwon, S. Y. Choi, K. U. Lee, J. Y. Park, I. J. Moon, J. G. Park, M. Yoshizumi, Y. Ouchi, and I. K. Lee (2002), Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo, Circ. Res. 90, 1325-1332
- Park, K. K., J, D. Ahn, I. K. Lee, J. Magae, N. H. Heintz, J. Y. Kwak, Y. C. Lee, Y. S. Cho, H. C. Kim, Y. M. Chae, Y. Kim, C. H. Kim, and Y. C. Chang (2003), Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP, Biochem. Biophys. Res. Commun. 308, 689-697
- Ahn, J. D., C. H. Kim, J. Magae, Y. H. Kim, H. J. Kim, K. K. Park, S. Hong, K. G. Park, I. K. Lee, and Y. C. Chang (2003), E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells, Biochem. Biophys. Res. Commun. 310, 1048-1053